Professor Avril Robertson
Professor

Avril Robertson

Email: 
Phone: 
+61 7 334 60586

Availability

Professor Avril Robertson is:
Available for supervision

Qualifications

  • Masters (Research), University of St Andrews
  • Doctor of Philosophy, University of St Andrews
  • Postgraduate Diploma in Higher Education, The University of Queensland
  • Postgraduate Diploma in Higher Education, Institution to be confirmed

Search Professor Avril Robertson’s works on UQ eSpace

134 works between 1999 and 2025
All (134) Journal Article (99) Book Chapter (1) Conference Publication (27) Other Outputs (7)

101 - 120 of 134 works

2016

Conference Publication

NLRP3 inflammasome-mediated, IL-1 beta-dependent inflammatory responses drive severe, steroid-insensitive asthma

Kim, R., Pinkerton, J., Essilfie, A., Robertson, A., Baines, K., Mayall, J., Starkey, M., Wark, P., Gibson, P., O'Neill, L., Cooper, M., Horvat, J. and Hansbro, P. (2016). NLRP3 inflammasome-mediated, IL-1 beta-dependent inflammatory responses drive severe, steroid-insensitive asthma. Thoracic Society of Australia & New Zealand and the Australian & New Zealand Society of Respiratory Science, Annual Scientific Meeting, Perth, WA, Australia, 1–6 April 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/resp.12754_11

NLRP3 inflammasome-mediated, IL-1 beta-dependent inflammatory responses drive severe, steroid-insensitive asthma

2016

Conference Publication

Nlrp3 Inflammasome-Mediated, Il-1 beta-Dependent Inflammatory Responses Drive Severe, Steroid-Insensitive Asthma

Kim, R. Y., Pinkerton, J. W., Essilfie, A. -T., Robertson, A. A., Baines, K. J., Mayall, J. R., Starkey, M. R., Wark, P. A., Gibson, P. G., O'Neill, L. A., Cooper, M. A., Horvat, J. C. and Hansbro, P. M. (2016). Nlrp3 Inflammasome-Mediated, Il-1 beta-Dependent Inflammatory Responses Drive Severe, Steroid-Insensitive Asthma. International Conference of the American Thoracic Society (ATS), San Francisco, California, 13-18 May 2016 . New York, NY, United States: American Thoracic Society.

Nlrp3 Inflammasome-Mediated, Il-1 beta-Dependent Inflammatory Responses Drive Severe, Steroid-Insensitive Asthma

Featured

2016

Journal Article

Strain- and host species-specific inflammasome activation, IL-1β release, and cell death in macrophages infected with uropathogenic Escherichia coli.

Schaale, K., Peters, K. M., Murthy, A. M., Fritzsche, A. K., Phan, M.-D., Totsika, M., Robertson, A. A. B., Nichols, K. B., Cooper, M. A., Stacey, K. J., Ulett, G. C., Schroder, K., Schembri, M. A. and Sweet, M. J. (2016). Strain- and host species-specific inflammasome activation, IL-1β release, and cell death in macrophages infected with uropathogenic Escherichia coli.. Mucosal Immunology, 9 (1), 124-136. doi: 10.1038/mi.2015.44

Strain- and host species-specific inflammasome activation, IL-1β release, and cell death in macrophages infected with uropathogenic Escherichia coli.

2016

Conference Publication

Evidence against a role for NLRP3-driven inflammation in the db/db mouse model of type 2 diabetes

Kammoun, H. L., Allen, T. L., Henstridge, D. C., Barre, S., Coll, R. C., Butler, M. S., Roberston, A. A. B., O'Neill, L. A., Murphy, A. J., Cooper, M. A. and Febbraio, M. A. (2016). Evidence against a role for NLRP3-driven inflammation in the db/db mouse model of type 2 diabetes. International Congress of Immunology (ICI), Melbourne, VIC, Australia, 21-26 August 2016. Weinheim, Germany: Wiley - VCH Verlag. doi: 10.1002/eji.201670200

Evidence against a role for NLRP3-driven inflammation in the db/db mouse model of type 2 diabetes

2016

Conference Publication

Autocrine NLPR3 inflammasome activity is critical to normal adaptive immunity via regulation of IFN-gamma in CD4(+) T cells

West, Erin E., Arbore, Giuseppina, Robertson, Avril A. B., Klos, Andreas, Woodruff, Trent M., O'Neill, Luke A., Coll, Rebecca C., Sher, Alan, Leonard, Warren J., Koehl, Joerg, Monk, Pete, Cooper, Matthew A., Afzali, Behdad, Lachmann, Helen J., Cope, Andrew P., Mayer-Barber, Katrin and Kemper, Claudia (2016). Autocrine NLPR3 inflammasome activity is critical to normal adaptive immunity via regulation of IFN-gamma in CD4(+) T cells. Annual Meeting of the American Association of Immunologists (AAI), Seattle, WA, United States, 13-17 May 2016. Bethesda, MD, United States: American Association of Immunologists.

Autocrine NLPR3 inflammasome activity is critical to normal adaptive immunity via regulation of IFN-gamma in CD4(+) T cells

2016

Conference Publication

Role of inflammation, vasoconstriction and oxidative stress in the enhanced pressor response to angiotensin II in aged mice

Dinh, Q. N., Drummond, G. R., Kemp-Harper, B. K., Diep, H., Robertson, A. A. B., Cooper, M. A., Sobey, C. G. and Chrissobolis, S. (2016). Role of inflammation, vasoconstriction and oxidative stress in the enhanced pressor response to angiotensin II in aged mice. 37th Annual Scientific Meeting of The High Blood Pressure Research Council Of Australia, Melbourne, VIC, Australia, 2-4 December 2015. Philadelphia, PA, United States: Lippincott Williams & Wilkins. doi: 10.1161/HYP.0000000000000042

Role of inflammation, vasoconstriction and oxidative stress in the enhanced pressor response to angiotensin II in aged mice

2015

Journal Article

NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5

Baker, Paul J., Boucher, Dave, Bierschenk, Damien, Tebartz, Christina, Whitney, Paul G., D'Silva, Damian B, Tanzer, Marco J., Monteleone, Mercedes, Robertson, Avril A.B., Cooper, Matthew A., Alvarez-Diaz, Silvia, Herold, Marco J., Bedoui, Sammy, Schroder, Kate and Masters, Seth L. (2015). NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. European Journal of Immunology, 45 (10), 2918-2926. doi: 10.1002/eji.201545655

NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5

2015

Journal Article

The inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induce hypertension in mice

Krishnan, S. M., Dowling, J. K., Ling, Y. H., Diep, H., Chan, C. T., Ferens, D., Kett, M. M., Pinar, A., Samuel, C. S., Vinh, A., Arumugam, T. V., Hewitson, T. D., Kemp-Harper, B. K., Robertson, A. A. B., Cooper, M. A., Latz, E., Mansell, A., Sobey, C. G. and Drummond, G. R. (2015). The inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induce hypertension in mice. British Journal of Pharmacology, 173 (4), 752-765. doi: 10.1111/bph.13230

The inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induce hypertension in mice

2015

Journal Article

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

Coll, Rebecca C., Robertson, Avril A. B., Chae, Jae Jin, Higgins, Sarah C., Muñoz-Planillo, Raúl, Inserra, Marco C., Vetter, Irina, Dungan, Lara S., Monks, Brian G., Stütz, Andrea, Croker, Daniel E., Butler, Mark S., Haneklaus, Moritz, Sutton, Caroline E., Núñez, Gabriel, Latz, Eicke, Kästner, Daniel L., Mills, Kingston H. G., Masters, Seth L., Schroder, Kate, Cooper, Matthew A. and O'Neill, Luke A. J. (2015). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 21 (3), 248-257. doi: 10.1038/nm.3806

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

2015

Conference Publication

Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH

Mridha, Auvro R., Wree, Alexander, Robertson, Avril A., Teoh, Narci C., Cooper, Matthew A., Feldstein, Ariel E. and Farrell, Geoffrey C. (2015). Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH. 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, United States, 13-17 November 2015. Hoboken, NJ, United States: John Wiley & Sons. doi: 10.1002/hep.28175

Blocking the NLRP3 inflammasome prevents inflammatory recruitment and fibrotic progression in experimental NASH

2015

Conference Publication

Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritis

McGarry, T., Coll, R.C., Robertson, A.A.B., Cooper, M.A., O’Neill, L.A., Veale, D.J. and Fearon, U. (2015). Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritis. 35th European Workshop for Rheumatology Research, Budapest, Hungary, 5-7 March 2015. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2015-207259.144

Novel compound cytokine release inhibitory drug 3 (CRID3) inhibits the NLRP3 inflammasome in rheumatoid arthritis

2015

Conference Publication

An optimized whole blood assay measuring expression and activity of NLRP3-, NLRC4 and AIM2-inflammasomes

Grinstein, L., Luksch, H., Robertson, A. A. B., Cooper, M. A., Winkler, S. and Rösen-Wolff, A. (2015). An optimized whole blood assay measuring expression and activity of NLRP3-, NLRC4 and AIM2-inflammasomes. 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases, Dresden, Germany, 30 September - 3 October 2015. BMC. doi: 10.1186/1546-0096-13-S1-O51

An optimized whole blood assay measuring expression and activity of NLRP3-, NLRC4 and AIM2-inflammasomes

2015

Conference Publication

The effect of novel compound MCC950 On the NLRP3 inflammasome in the RA joint

McGarry, T., Robertson, A. A., Orr, C., Coll, R. C., Cooper, M. A., O'Neill, L. A., Veale, D. J. and Fearon, U. (2015). The effect of novel compound MCC950 On the NLRP3 inflammasome in the RA joint. Annual European Congress of Rheumatology, Rome, Italy, 10-13 July 2015. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2015-eular.3985

The effect of novel compound MCC950 On the NLRP3 inflammasome in the RA joint

2015

Conference Publication

Activation of Redox-Sensitive Inflammasomes Underlies the Biological Phenotype of Myelodysplastic Syndromes

Basiorka, A., Mcgraw, K., Eksioglu, E., Chen, X., Johnson, J., Padron, E., Komrokji, R., Sokol, L., Coll, R., O'Neill, L., Cooper, M., Robertson, A., Wei, S. and List, A. (2015). Activation of Redox-Sensitive Inflammasomes Underlies the Biological Phenotype of Myelodysplastic Syndromes. 13th International Symposium on Myelodysplastic Syndromes (MDS), Washington DC, United States, Apr 29-May 02, 2015. Kidlington, Oxford, United Kingdom: Pergamon Press. doi: 10.1016/S0145-2126(15)30033-3

Activation of Redox-Sensitive Inflammasomes Underlies the Biological Phenotype of Myelodysplastic Syndromes

2015

Conference Publication

Selective inhibition of the NLRP3 inflammasome dose-dependently reduces infarct size and preserves cardiac function in a porcine model of myocardial infarction

Van Hout, G. P. J., Bosch, L., Ellenbroek, G. H. J. M., Cooper, M., Van Solinge, W. W., De Jager, S. C. A., Robertson, A., Pasterkamp, G. and Hoefer, I. E. (2015). Selective inhibition of the NLRP3 inflammasome dose-dependently reduces infarct size and preserves cardiac function in a porcine model of myocardial infarction. Congress of the European Society of Cardiology (ESC), London, United Kingdom, 29 August-2 September 2015. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/eurheartj/ehv400

Selective inhibition of the NLRP3 inflammasome dose-dependently reduces infarct size and preserves cardiac function in a porcine model of myocardial infarction

2014

Journal Article

Natural product and natural product derived drugs in clinical trials

Butler, Mark S., Robertson, Avril A. B. and Cooper, Matthew A. (2014). Natural product and natural product derived drugs in clinical trials. Natural Product Reports, 31 (11), 1612-1661. doi: 10.1039/c4np00064a

Natural product and natural product derived drugs in clinical trials

2014

Journal Article

Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction

Greenhill, Claire J., Jones, Gareth W., Nowell, Mari A., Newton, Zarabeth, Harvey, Ann K., Moideen, Abdul N., Collins, Fraser L., Bloom, Anja C., Coll, Rebecca C., Robertson, Avril A. B., Cooper, Matthew A., Rosas, Marcela, Taylor, Philip R., O'Neill, Luke A., Humphreys, Ian R., Williams, Anwen S. and Jones, Simon A. (2014). Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Research and Therapy, 16 (4) 419. doi: 10.1186/s13075-014-0419-y

Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction

2014

Conference Publication

Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cells

Arbore, Giuseppina, Fara, Antonella F., Coll, Rebecca, Robertson, Avril, Cooper, Matthew, O'Neill, Luke A. J., Lavender, Paul, Cope, Andrew, Lachmann, Helen J. and Kemper, Claudia (2014). Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cells. 25th International Complement Workshop, Rio de Janeiro, Brazil, 14-18 September 2014. Kidlington, Oxford, United Kingdom: Pergamon Press. doi: 10.1016/j.molimm.2014.07.010

Control of the human Th1 response via autocrine complement-regulated NLRP3 inflammasome activation within CD4(+) T cells

2014

Conference Publication

What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH

Gan, L. T., Van Rooyen, D. M., Cooper, M., Robertson, A., Masters, S., Teoh, N. and Farrell, G. (2014). What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH. Australian Gastroenterology Week, Broadbeach, QLD, Australia, 22-24 october 2014. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.12736

What causes Kupffer cell activation in NAFLD? HMGB1, TLR4, crystals and NLRP3 inflammasome link free cholesterol to inhibitable pro-inflammatory pathways in NASH

2014

Conference Publication

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

McGarry, Trudy, Connolly, Mary, Coll, Rebecca C., Robertson, Avril A. B., Cooper, Matthew A., O'Neill, Luke A., Veale, Douglas J. and Fearon, Ursula (2014). Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis. 78th Annual Meeting of the American College of Rheumatology/49th Annual Meeting of the Association of Rheumatology Health Professionals, Boston, MA United States, 14-19 November 2014. Hoboken, NJ United States: John Wiley and Sons.

Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis

Current funding

  • 2022 - 2025
    Inhibiting ASC with small molecules for treatment of inflammatory diseases
    NHMRC IDEAS Grants
    Open grant

Past funding

  • 2022 - 2023
    Targeting inflammation to treat dementia (Lead by La Trobe)
    The Cass Foundation Limited
    Open grant
  • 2021 - 2024
    The NLRP3 inflammasome in the pathogenesis of polycystic kidney disease (PKD Australia administered by La Trobe University)
    La Trobe University
    Open grant
  • 2020 - 2023
    Novel Broad Spectrum Antifungals Active Against Drug Resistant Candida Auris
    NHMRC IDEAS Grants
    Open grant
  • 2018 - 2022
    Validating the NLRP3 Inflammasome as a Therapeutic Target in Motor Neuron Disease
    NHMRC Project Grant
    Open grant
  • 2017 - 2018
    A Pharmacology Screening Facility to Accelerate Drug Discovery and Development
    UQ Major Equipment and Infrastructure
    Open grant
  • 2017 - 2019
    Inflammatory pathways to liver fibrosis in non-alcoholic and alcoholic steatohepatitis: reversal by NLRP3 inhibitors (NHMRC Project Grant administered by ANU)
    Australian National University
    Open grant
  • 2017 - 2021
    Novel NLRP3 inhibitors for asthma therapy
    NHMRC Development Grant
    Open grant
  • 2016 - 2020
    Blocking inflammasome-induced neuroinflammation in PD with a potent, orally available small molecule
    The Michael J Fox Foundation Therapeutic Pipeline Program
    Open grant
  • 2015 - 2017
    Pharmacological targeting of the NLRP3 inflammasome in pre-clinical models of Parkinson's disease using a potent orally active inhibitor
    The Michael J Fox Foundation for Parkinsons Research
    Open grant
  • 2015 - 2017
    Inhibitors of NLRP3 activation for treatment of inflammatory CNS diseases
    NHMRC Project Grant
    Open grant
  • 2013 - 2016
    Novel immunomodulatory agents for type II diabetes through targeting the NLRP3 inflammasome signalling cascade
    Department of Innovation, Industry, Science and Research - Australia-India Strategic Research Fund
    Open grant
  • 2012 - 2013
    IMPDH as an antifungal drug target
    Therapeutic Innovation Australia Limited
    Open grant

Availability

Professor Avril Robertson is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Enquiries

For media enquiries about Professor Avril Robertson's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au